{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:36:08Z","timestamp":1765233368792},"reference-count":26,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,9,1]]},"DOI":"10.2169\/internalmedicine.8786-21","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T22:12:56Z","timestamp":1661983976000},"page":"2567-2572","source":"Crossref","is-referenced-by-count":3,"title":["Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome"],"prefix":"10.2169","volume":"61","author":[{"given":"Tomoki","family":"Suichi","sequence":"first","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonoko","family":"Misawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Sekiguchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"},{"name":"Department of Neurology, JR Tokyo General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumoto","family":"Shibuya","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keigo","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Kano","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Aotsuka","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Otani","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Morooka","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shokichi","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Mimura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Japan"},{"name":"Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Ohwada","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Japan"},{"name":"Department of Hematology, International University of Health and Welfare School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chiba University Hospital, Japan"},{"name":"Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Dispenzieri A. POEMS syndrome: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol 96: 872-888, 2021.","DOI":"10.1002\/ajh.26240"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Watanabe O, Arimura K, Kitajima I, Osame M, Maruyama I. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 347: 702, 1996.","DOI":"10.1016\/S0140-6736(96)91261-1"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. D&apos;Souza A, Lacy M, Gertz M, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood 120: 56-62, 2012.","DOI":"10.1182\/blood-2012-04-423178"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Li J, Duan MH, Wang C, et al. Impact of pretransplant induction therapy on autologous stem cell transplantation for patients with newly diagnosed POEMS syndrome. Leukemia 31: 1375-1381, 2017.","DOI":"10.1038\/leu.2017.27"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Ohwada C, Sakaida E, Kawajiri-Manako C, et al. Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome. Blood 131: 2173-2176, 2018.","DOI":"10.1182\/blood-2017-07-795385"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Li J, Zhang W, Jiao L, et al. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Blood 117: 6445-6449, 2011.","DOI":"10.1182\/blood-2010-12-328112"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Misawa S, Sato Y, Katayama K, et al. Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 15: 1129-1137, 2016.","DOI":"10.1016\/S1474-4422(16)30157-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Nozza A, Terenghi F, Gallia F, et al. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol 179: 748-755, 2017.","DOI":"10.1111\/bjh.14966"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Li J, Huang XF, Cai QQ, et al. A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Am J Hematol 93: 803-809, 2018.","DOI":"10.1002\/ajh.25100"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Suichi T, Misawa S, Nagashima K, et al. Lenalidomide treatment for thalidomide-refractory POEMS syndrome: a prospective single-arm clinical trial. Intern Med 59: 1149-1153, 2020.","DOI":"10.2169\/internalmedicine.3800-19"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. He H, Fu W, Du J, Jiang H, Hou J. Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen. Br J Haematol 181: 126-128, 2018.","DOI":"10.1111\/bjh.14497"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Riva M, Lessi F, Berno T, et al. Bortezomib-based regimens in patients with POEMS syndrome: a case series in newly diagnosed and relapsed patients. Leuk Lymphoma 60: 2067-2070, 2019.","DOI":"10.1080\/10428194.2018.1564048"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kaygusuz I, Tezcan H, Cetiner M, Kocakay O, Uzay A, Bayik M. Bortezomib: a new therapeutic option for POEMS syndrome. Eur J Haematol 84: 175-177, 2010.","DOI":"10.1111\/j.1600-0609.2009.01341.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Li J, Zhang W, Kang WY, Cao XX, Duan MH, Zhou DB. Bortezomib and dexamethasone as first-line therapy for a patient with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes syndrome complicated by renal failure. Leuk Lymphoma 53: 2527-2529, 2012.","DOI":"10.3109\/10428194.2012.690515"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kourelis TV, Buadi FK, Kumar SK, et al. Long-term outcome of patients with POEMS syndrome: an update of the Mayo Clinic experience. Am J Hematol 91: 585-589, 2016.","DOI":"10.1002\/ajh.24356"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Suichi T, Misawa S, Beppu M, et al. Prevalence, clinical profiles, and prognosis of POEMS syndrome in Japanese nationwide survey. Neurology 93: e975-e983, 2019.","DOI":"10.1212\/WNL.0000000000008062"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 95: 548-567, 2020.","DOI":"10.1002\/ajh.25791"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374: 1621-1634, 2016.","DOI":"10.1056\/NEJMoa1516282"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Facon T, Venner CP, Bahlis NJ, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 137: 3616-3628, 2020.","DOI":"10.1182\/blood.2020008787"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Suichi T, Misawa S, Sato Y, et al. Proposal of new clinical diagnostic criteria for POEMS syndrome. J Neurol Neurosurg Psychiatry 90: 133-137, 2019.","DOI":"10.1136\/jnnp-2018-318514"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Misawa S, Sato Y, Katayama K, et al. Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study. BMJ Open 5: e009157, 2015.","DOI":"10.1136\/bmjopen-2015-009157"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Muz B, Ghazarian RN, Ou M, Luderer MJ, Kusdono HD, Azab AK. Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Des Devel Ther 10: 217-226, 2016.","DOI":"10.2147\/DDDT.S93602"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Kr\u00f6nke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343: 301-305, 2014.","DOI":"10.1126\/science.1244851"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343: 305-309, 2014.","DOI":"10.1126\/science.1244917"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Chauhan D, Tian Z, Zhou B, et al. <i>In vitro<\/i> and <i>in vivo<\/i> selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 17: 5311-5321, 2011.","DOI":"10.1158\/1078-0432.CCR-11-0476"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kumar S, Moreau P, Hari P, et al. Management of adverse events associated with ixazomib plus lenalidomide\/dexamethasone in relapsed\/refractory multiple myeloma. Br J Haematol 178: 571-582, 2017.","DOI":"10.1111\/bjh.14733"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/17\/61_8786-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:19:48Z","timestamp":1715231988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/17\/61_8786-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":26,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8786-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"article-number":"8786-21"}}